Skip to main content
Midas Edge

TELA Bio, Inc.

For the period ended Dec 31, 2024. Filed Mar 21, 2025.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Mar 21, 2025

TELA$0.80-7.5%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Consolidated Statements of Stockholders’ Equity

(In thousands, except share amounts)

​​​​​​​​​​​​​​​​​​
​ · ​ · ​ · ​ · ​ · ​ · Accumulated · ​ · ​ · ​ · ​
​ · ​ · ​ · ​ · ​ · ​ · ​ · Additional · ​ · other · ​ · ​ · ​ · ​ · ​ · ​
​ · ​ · Common stock · ​ · paid‑in · ​ · comprehensive · ​ · Accumulated · ​ · ​ · ​
​ · Shares · Amount · capital · income (loss) · deficit · Total
Balance at January 1, 2022​14,529,577​$15​$250,064​$(52)​$(229,929)​$20,098
Vesting of common stock previously subject to repurchase​29​—​—​—​—​​—
Vesting of restricted stock units and exercise of stock options​44,346​—​19​—​—​​19
Issuance of common stock under the employee stock purchase plan​4,523​​—​​50​​—​​—​​50
Shares withheld for employee taxes​(13,448)​​​​​(157)​​​​​​​​(157)
Foreign currency translation adjustment​—​​—​​—​​202​​—​​202
Stock‑based compensation expense​—​—​3,989​—​—​3,989
Sale of common stock, net of underwriting discounts, commissions and offering costs​4,600,000​​4​​34,396​​​​​​​​34,400
Net loss​—​—​—​—​(44,296)​(44,296)
Balance at December 31, 202219,165,027​​19​​288,361​​150​​(274,225)​​14,305
Vesting of restricted stock units and exercise of stock options126,987​—​127​—​—​127
Issuance of common stock under the employee stock purchase plan​10,602​—​88​—​—​88
Shares withheld for employee taxes​(27,131)​​—​​(289)​​—​​—​​(289)
Foreign currency translation adjustment—​​—​​—​​(59)​​—​(59)
Stock‑based compensation expense—​—​5,032​—​—​5,032
Sale of common stock, net of underwriting discounts, commissions and offering costs​5,219,190​​5​​46,336​​—​​—​​46,341
Net loss—​—​—​—​(46,664)​(46,664)
Balance at December 31, 202324,494,675​​24​​339,655​​91​​(320,889)—​18,881
Vesting of restricted stock units and exercise of stock options229,606​1​225​—​—​226
Issuance of common stock under the employee stock purchase plan​58,994​​—​​281​​—​​—​​281
Shares withheld for employee taxes​(57,563)​​—​​(369)​​—​​—​​(369)
Foreign currency translation adjustment—​—​—​(1)​—​(1)
Stock‑based compensation expense​—​​—​​4,362​​—​​—​​4,362
Sale of common stock and pre-funded warrants, net of underwriting discounts, commissions and offering costs​14,670,000​​14​​42,905​​—​​—​​42,919
Net loss—​—​—​—​(37,841)​(37,841)
Balance at December 31, 202439,395,712​$39​$387,059​$90​$(358,730)​$28,458
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.